Zacks Investment Research lowered shares of Sientra, Inc. (NASDAQ:SIEN) from a hold rating to a sell rating in a research report released on Tuesday.
According to Zacks, “Sientra, Inc. is a medical aesthetics company. The Company offers plastic surgery implantable devices for cosmetic and reconstructive surgery, including Breast Implants, Tissue Expanders, Body Contouring, Implants and Specialty Products. Sentra’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures. It also offers a range of other aesthetic and specialty products. Sientra, Inc. is headquartered in Santa Barbara, California. “
A number of other equities research analysts have also issued reports on the stock. Lake Street Capital reiterated a buy rating and set a $15.00 target price (up from $11.00) on shares of Sientra in a report on Tuesday, August 8th. Stephens assumed coverage on shares of Sientra in a report on Tuesday, July 11th. They set an overweight rating and a $12.00 target price on the stock. Finally, ValuEngine upgraded shares of Sientra from a sell rating to a hold rating in a report on Thursday, June 22nd.
Sientra (SIEN) opened at 10.40 on Tuesday. The company has a 50-day moving average of $10.58 and a 200-day moving average of $9.02. Sientra has a 52 week low of $6.92 and a 52 week high of $11.47. The company’s market cap is $200.78 million.
Sientra (NASDAQ:SIEN) last released its earnings results on Wednesday, August 9th. The medical instruments supplier reported ($0.55) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.59) by $0.04. The company had revenue of $8.20 million for the quarter, compared to analyst estimates of $6.97 million. Sientra had a negative net margin of 173.83% and a negative return on equity of 52.30%. The firm’s revenue for the quarter was up 32.3% on a year-over-year basis. On average, equities research analysts predict that Sientra will post ($3.07) EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “Zacks Investment Research Downgrades Sientra, Inc. (SIEN) to Sell” was originally posted by BNB Daily and is owned by of BNB Daily. If you are accessing this piece on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.baseball-news-blog.com/2017/08/19/zacks-investment-research-downgrades-sientra-inc-sien-to-sell.html.
Several large investors have recently made changes to their positions in SIEN. Wells Fargo & Company MN raised its stake in shares of Sientra by 0.3% in the first quarter. Wells Fargo & Company MN now owns 12,871 shares of the medical instruments supplier’s stock worth $108,000 after buying an additional 40 shares during the last quarter. Bank of New York Mellon Corp raised its stake in shares of Sientra by 0.5% in the first quarter. Bank of New York Mellon Corp now owns 51,760 shares of the medical instruments supplier’s stock worth $436,000 after buying an additional 250 shares during the last quarter. Blair William & Co. IL raised its stake in shares of Sientra by 2.0% in the first quarter. Blair William & Co. IL now owns 30,758 shares of the medical instruments supplier’s stock worth $299,000 after buying an additional 594 shares during the last quarter. Parametric Portfolio Associates LLC raised its stake in shares of Sientra by 14.4% in the first quarter. Parametric Portfolio Associates LLC now owns 16,410 shares of the medical instruments supplier’s stock worth $138,000 after buying an additional 2,065 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in shares of Sientra by 23.4% in the second quarter. Dimensional Fund Advisors LP now owns 18,660 shares of the medical instruments supplier’s stock worth $181,000 after buying an additional 3,534 shares during the last quarter. Institutional investors and hedge funds own 78.57% of the company’s stock.
Sientra Company Profile
Sientra, Inc is a medical aesthetics company. The Company’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures, which it offers in over 190 variations of shapes, sizes and textures. The Company sells its breast implants and breast tissue expanders, or breast products to plastic surgeons.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sientra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra Inc. and related companies with MarketBeat.com's FREE daily email newsletter.